ALK and non-small cell lung carcinoma: Testing lung adenocarcinomas for ALK rearrangements has become standard practice since remarkable responses in ALK rearrangement-positive NSCLC patients treated with oral TKIs (i.e., alectinib, brigatinib, ceritinib, crizotinib, lorlatinib) have been documented [84].